BioCardiaSTU:6JU0 17 Piotroski F-Score is 3 as of Jul. 09, 2026, which is at its 10-year median of 3.00. GuruFocus rates STU:6JU0 with a GF Score™ of 17/100 and a GF Value™ of €0.01. The stock has 1 warning sign investors should review. Among 1,331 Biotechnology companies, BioCardia ranks better than 54.7% on this metric.
Warning Sign:
Piotroski F-Score of 3 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
BioCardia has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for BioCardia's Piotroski F-Score or its related term are showing as below:
STU:6JU0'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 3 Max: 7
Current: 3
During the past 13 years, the highest Piotroski F-Score of BioCardia was 7. The lowest was 1. And the median was 3.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
BioCardia Piotroski F-Score Related Terms
BioCardia Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for BioCardia's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:6JU0 vs GRTX, CELU, KTTA: Piotroski F-Score Comparison
For the Biotechnology subindustry, BioCardia's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioCardia Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioCardia's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where BioCardia's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
BioCardia's current Net Income (TTM) was -6.69.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
BioCardia's return on assets of this year was -3.33732535. BioCardia's return on assets of last year was -3.16267748.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
BioCardia's current ratio of this year was 0.41032043. BioCardia's current ratio of last year was 0.36275493.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
BioCardia's number of shares in issue this year was 10.812. BioCardia's number of shares in issue last year was 4.636.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
BioCardia's gross margin of this year was . BioCardia's gross margin of last year was 1.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
BioCardia's asset turnover of this year was 0. BioCardia's asset turnover of last year was 0.00121704.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
1
+
1
+
1
+
0
+
0
+
0
=
3
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
BioCardia has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
BioCardia (STU:6JU0) has a Piotroski F-Score of 3 as of Jul. 09, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on BioCardia and its competitors. This is near median its historical median of 3.00. Over the past decade, BioCardia's Piotroski F-Score has ranged from 1.00 to 7.00. According to the industry distribution chart, BioCardia ranks #603 out of 1331 companies in the Biotechnology industry, placing it in the top 45.3%.
Is BioCardia's Piotroski F-Score too high?
BioCardia's current Piotroski F-Score of 3 is near median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 7.00. The Biotechnology industry median Piotroski F-Score is 3.00. BioCardia's value of 3 is 0% at this industry median. Based on the distribution chart, BioCardia ranks #603 out of 1331 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioCardia has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does BioCardia's Piotroski F-Score compare to GRTX and CELU?
According to the Biotechnology industry distribution chart, BioCardia ranks #603 out of 1331 companies for Piotroski F-Score. This puts BioCardia in the upper half of its industry. The industry median Piotroski F-Score is 3.00. BioCardia's value of 3 is 0% at this benchmark. Historically, BioCardia's own Piotroski F-Score has ranged from 1.00 to 7.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 3.00, BioCardia has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,331 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioCardia's current Piotroski F-Score of 3 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on BioCardia and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioCardia's current Piotroski F-Score is 3, which is near median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCardia stock overvalued right now?
BioCardia (STU:6JU0) has a current Piotroski F-Score of 3. The stock's GF Value™ is €0.01, compared to a current price of €0.27 — trading 2600% above its estimated fair value. The current Piotroski F-Score is 3, which is near median its 10-year median of 3.00 and 0% at the Biotechnology industry median of 3.00. BioCardia's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For BioCardia (STU:6JU0), the current Piotroski F-Score is 3 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioCardia (STU:6JU0) Overvalued in 2026?
Based on GuruFocus' analysis, BioCardia stock appears to be overvalued.
The current stock price of €0.27 is trading 2600% above its estimated GF Value™ of €0.01.
Key valuation signals for STU:6JU0:
Piotroski F-Score: 3 (near median its 10-year median of 3.00)
GF Value™: €0.01 vs. price of €0.27 (2600% above fair value)
Industry Position: 0% at the Biotechnology median (#603 of 1331)
No single metric tells the full story. See the STU:6JU0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
17GF Score
Get the complete analysis for STU:6JU0
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6JU0 has been successfully added to your 
